CN114098074A - 羟基红花黄色素a在增强耐力中的应用 - Google Patents
羟基红花黄色素a在增强耐力中的应用 Download PDFInfo
- Publication number
- CN114098074A CN114098074A CN202111317801.7A CN202111317801A CN114098074A CN 114098074 A CN114098074 A CN 114098074A CN 202111317801 A CN202111317801 A CN 202111317801A CN 114098074 A CN114098074 A CN 114098074A
- Authority
- CN
- China
- Prior art keywords
- hydroxysafflor yellow
- endurance
- skeletal muscle
- composition
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 title claims abstract description 67
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 17
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 37
- 230000036541 health Effects 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000003647 oxidation Effects 0.000 claims description 16
- 238000007254 oxidation reaction Methods 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 230000034659 glycolysis Effects 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000029549 Muscle injury Diseases 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 208000017667 Chronic Disease Diseases 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000004088 simulation Methods 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 238000012549 training Methods 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 230000000181 anti-adherent effect Effects 0.000 claims description 2
- 239000002518 antifoaming agent Substances 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000006046 creatine Substances 0.000 claims description 2
- 229960003624 creatine Drugs 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 229940037395 electrolytes Drugs 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008394 flocculating agent Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 208000001076 sarcopenia Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000007103 stamina Effects 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 235000021310 complex sugar Nutrition 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- -1 glidants Substances 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000000446 fuel Substances 0.000 abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 12
- 239000008103 glucose Substances 0.000 abstract description 12
- 229930014626 natural product Natural products 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 21
- 238000011529 RT qPCR Methods 0.000 description 13
- 239000003925 fat Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 244000020518 Carthamus tinctorius Species 0.000 description 11
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 11
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 9
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 7
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 7
- 101000760747 Homo sapiens Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 7
- 102000001105 Phosphofructokinases Human genes 0.000 description 7
- 108010069341 Phosphofructokinases Proteins 0.000 description 7
- 102000000019 Sterol Esterase Human genes 0.000 description 7
- 108010055297 Sterol Esterase Proteins 0.000 description 7
- 102100024591 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 101001129187 Homo sapiens Patatin-like phospholipase domain-containing protein 2 Proteins 0.000 description 6
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 6
- 230000004130 lipolysis Effects 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 102100030338 Hexokinase-1 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000002414 glycolytic effect Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000037080 exercise endurance Effects 0.000 description 3
- 230000002366 lipolytic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000012737 Electron-Transferring Flavoproteins Human genes 0.000 description 1
- 108010079426 Electron-Transferring Flavoproteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000010093 guan-xin-ning Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229930194301 safflor yellow Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了羟基红花黄色素A在增强耐力中的应用,属于天然产物健康营养领域。本发明用羟基红花黄色素A灌胃小鼠,结果表明羟基红花黄色素A可以显著提高小鼠的耐力运动表现,促进小鼠骨骼肌中燃料选择从葡萄糖转向脂肪。本发明选用天然产物羟基红花黄色素A来增强耐力运动表现,具有原料来源广、价格亲民、无毒副作用、效果优良的好处。
Description
技术领域
本发明涉及羟基红花黄色素A在增强耐力中的应用,属于天然产物健康营养领域。
背景技术
在运动过程中,运动时间或运动强度的不同都会直接导致身体所需能量不同。在马拉松和自行车等耐力运动中,碳水化合物和脂肪的氧化代谢几乎提供了所有用于收缩骨骼肌所需的腺嘌呤核苷三磷酸(ATP)。其中,碳水化合物为长时间耐力运动提供主要的所需能量。运动过程中,肌糖原的储备多少会直接影响着身体骨骼肌的运动能力,碳水化合物耗竭是人类和啮齿动物耐力的一个主要限制。
骨骼肌燃料选择偏好是指,在运动过程中,骨骼肌对供能能源物质的选择具有偏好性,其中,能源物质包括碳水化合物、脂肪酸和氨基酸;通常碳水化合物的氧化,特别是肌肉糖原的氧化,在高强度的运动中占主导地位,而脂肪的氧化在低强度的运动中更重要。最近的一些研究表明,在耐力运动中将骨骼肌燃料选择偏好从葡萄糖转移到脂肪可以有效对抗疲劳和延长耐力表现。此外,这种代谢燃料策略被证明可以提高代谢灵活性和能量资源效率,并增强运动相关的健康和长寿益处。
己糖激酶(HK),磷酸果糖激酶(PFK),丙酮酸激酶(PKM)是糖酵解途径中的不可逆步骤的三个关键酶,它们的活性直接影响着整个糖酵解代谢途径的速度和方向。脂肪酸转运蛋白(FATP)、肉碱棕榈酰转移酶1A(CPT1A)、酰基辅酶A脱氢酶极长链(ACADVL)、电子转移黄素蛋白B(ETFB)则是参与脂肪酸转运和氧化的基因。除了糖酵解、脂肪酸氧化在骨骼肌能量代谢的公认作用外,考虑到脂解产物可用于脂肪酸氧化,因而脂滴代谢也会影响骨骼肌能量代谢。由于甘油三酯脂酶(ATGL)和激素敏感脂肪酶(HSL)可以催化甘油三酯转化为脂肪酸,因此它们也参与到了骨骼肌能量代谢的过程中。
目前市面上增强耐力的功能性食品主要含有三大类营养成分。第一类是通过抗中枢神经系统疲劳从而增强耐力的营养素,如支链氨基酸,咖啡因等;第二类是通过补充能量从而增强耐力的营养素,如膳食ATP,磷酸肌酸,葡萄糖、一氧化氮,谷氨酰胺等,第三类是针对氧化应激介导的肌肉损伤的营养素,如维生素E,维生素C等。然而,这些物质在效果、副作用、安全性等方面仍存在一些问题。考虑到天然产物的低副作用,人们越来越关注低成本天然产物的鉴定,并将其用于增强耐力的产品中。
红花是菊科成员Carthamus tinctorius L.的干燥花,为一种高度分枝的一年生或二年生草本。由于这种作物的强主根系统使其能够很好地克服极端温度、干旱、盐碱地和碱等环境压力,因此红花几乎在世界范围内都有栽培。红花的花瓣是提取红色或黄色色素的良好资源,其中,羟基红花黄色素A是影响红花生物活性的主要化合物。羟基红花黄色素A除了作为天然食用色素应用于日常食品中,还被用作功能性成分,添加到一些药物配方中。许多研究表明羟基红花黄色素A对糖尿病、脂肪、高脂血症、骨质疏松症、心血管疾病等代谢疾病具有有益作用。然而,迄今为止,对羟基红花黄色素A促进骨骼肌燃料选择偏好从葡萄糖转移到脂肪从而增强耐力的作用方面还未见报道。
发明内容
[技术问题]
本发明要解决的技术问题是现有增强耐力的功能性食品所含的营养成分在副作用、安全性等方面仍存在一些问题。
[技术方案]
本发明提供羟基红花黄色素A或含羟基红花黄色素A的组合物在制备用于增强耐力的功能性食品或药品或保健品或运动模拟药中的用途。所述羟基红花黄色素A的结构式如图1所示。所述增强耐力是指燃烧脂肪、对抗运动性疲劳、增强机体的运动能力等,包括延长机体运动时间、抑制糖酵解相关基因表达,促进脂肪酸氧化相关基因表达。所述糖酵解基因包括:HK1、PFK、PKM。所述脂肪酸氧化相关基因包括脂肪酸氧化基因:FATP、CPT1A、ACADVL、ETFB,和脂肪分解基因:ATGL、HSL。
所述功能性食品包括:功能性饮料、功能性冲剂、功能性泡腾片、功能性饼干、功能性胶囊等。可以用于马拉松、自行车等耐力运动。
所述药品包括用于治疗骨骼肌慢性疾病和/或治疗骨骼肌损伤的药物,模拟运动刺激等的药物。所述骨骼肌慢性疾病包括:骨质疏松、肌少症、慢性骨骼肌损伤等。
所述保健品包括:用于提升耐力,缓解疲劳等的保健食品。
所述羟基红花黄色素A或含有羟基红花黄色素A的组合物能够增强运动耐力表现,是因为它们能够促进骨骼肌燃料选择偏好从葡萄糖转移到脂肪从而有效对抗疲劳和延长耐力表现。所述促进骨骼肌燃料选择偏好从葡萄糖转移到脂肪是指在指在一定剂量和范围内,羟基红花黄色素A刺激抑制肌细胞的葡萄糖摄取,降低肌细胞中的糖酵解基因HK1、PFK、PKM的表达和甘油三酯含量,增加脂肪酸氧化基因FATP、CPT1A、ACADVL、ETFB和脂肪分解基因ATGL、HSL的表达。促进骨骼肌燃料选择偏好从葡萄糖转移到脂肪有利于提高耐力运动的表现。
所述羟基红花黄色素A的来源可以是:红花、红花种子、红花粕、红花籽、红花四物汤、八味冠心宁胶囊等。
本发明还提供用于增强耐力表现的组合物,所述组合物为含有羟基红花黄色素A或羟基红花黄色素A衍生物的组合物。
所述组合物,还包括药学上接受的辅料,包括溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂、释放阻滞剂等。
所述组合物,还可以包含其他对机体耐力有利的补充成分。补充成分可选自蛋白质、氨基酸(分支或不分支)、糖(单糖或复合糖)、肌酐、电解质、肌酸、维生素、矿物质以及补充训练饮食的其他因子。
[有益效果]
(1)红花在中国新疆等地区广泛种植;富含羟基红花黄色素A的红花黄色素已被国家列为允许在食品中使用的食品添加剂。因此本发明选用天然产物羟基红花黄色素A来增强耐力,具有原料来源广、价格亲民、无毒副作用的好处。
(2)羟基红花黄色素A还是一种抗氧化剂,并且还具有抗炎,抗心血管疾病等其他有益的健康功效。因此除了增强耐力外,羟基红花黄色素A还能对人体产生健康益处。
(3)本发明通过灌胃羟基红花黄色素A标品对小鼠进行给药处理,发现羟基红花黄色素A显著提高了小鼠在疲劳转棒设备和跑步机上的运动时间。从油红染色和qPCR结果来看,给药组骨骼肌的脂滴含量显著减少,糖酵解相关基因显著下降,脂肪分解,脂肪酸氧化相关基因显著上升,改变了骨骼肌燃料选择的倾向。本发明继续在体外实验中进行验证,用羟基红花黄色素A纯品刺激分化的C2C12成肌细胞,从尼罗红染色和qPCR结果来看,与空白组相比,羟基红花黄色素A显著抑制了葡萄糖的摄取,减少了细胞中的脂滴含量。
附图说明
图1为羟基红花黄色素A的化学结构式。
图2表明在耐力运动中,补充羟基红花黄色素A对小鼠运动耐力表现的影响。数据用平均值±标准误差表示,每组三次平行。与对照相比,*,P<0.05;**,P<0.01;***,P<0.001(T检验)。
图3表明补充羟基红花黄色素A对小鼠骨骼肌糖酵解相关基因的影响。A-C分别表示用RT-qPCR分析HK1、PFK和PKM的mRNA水平。数据用平均值±标准误差表示,每组三次平行。与对照相比,*,P<0.05;**,P<0.01;***,P<0.001(单因素方差分析)。
图4表明补充羟基红花黄色素A对小鼠骨骼肌脂肪酸氧化相关基因的影响。A-D分别表示用RT-qPCR分析FATP、CPT1A、ACADVL和ETFB的mRNA水平。数据用平均值±标准误差表示,每组三次平行。与对照相比,*,P<0.05;**,P<0.01;***,P<0.001(单因素方差分析)。
图5表明补充羟基红花黄色素A对小鼠骨骼肌脂滴含量和脂肪分解相关基因的影响。(A)表示对小鼠比目鱼肌SOL、腓肠肌GAS进行油红染色。(B)表示用RT-qPCR分析脂解相关基因ATGL、HSL的mRNA水平。数据用平均值±标准误差表示,每组三次平行。与对照相比,*,P<0.05;**,P<0.01;***,P<0.001(单因素方差分析)。
图6羟基红花黄色素A处理不同浓度和不同时间后C2C12细胞糖酵解相关基因在mRNA水平中的表达变化。(A)表示分别用0、100、200、400μmol/L的羟基红花黄色素A处理C2C12细胞24h,用RT-qPCR分析HK1、PFK和PKM的mRNA水平。(B)表示用100μmol/L的羟基红花黄色素A分别处理C2C12细胞0、4、12、24h,用RT-qPCR分析HK1、PFK和PKM的mRNA水平。数据用平均值±标准误表示,每组三次平行。与对照相比,*,P<0.05;**,P<0.01;***,P<0.001(单因素方差分析)。
图7羟基红花黄色素A处理不同浓度和不同时间后C2C12细胞脂肪酸氧化的相关基因在mRNA水平中的表达变化。(A)表示分别用0、100、200、400μmol/L的羟基红花黄色素A处理C2C12细胞24h,用RT-qPCR分析FATP、CPT1A、ACADVL和ETFB的mRNA水平。(B)表示用100μmol/L的羟基红花黄色素A分别处理C2C12细胞0、4、12、24h,用RT-qPCR分析FATP、CPT1A、ACADVL和ETFB的mRNA水平。数据用平均值±标准误表示,每组三次平行。与对照相比,*,P<0.05;**,P<0.01;***,P<0.001(单因素方差分析)。
图8羟基红花黄色素A处理不同浓度和不同时间后C2C12细胞脂滴含量和脂肪分解相关基因在mRNA水平中的表达变化。通过尼罗红测定法测定细胞甘油三酯。棕榈酸在C2C12肌管中诱导过多的脂质积累,并显示了来自用HSYA处理的C2C12肌管的尼罗红染色的(A)代表性图像。尼罗红,红色;细胞核,蓝色。(B)表示分别用0、100、200、400μmol/L的羟基红花黄色素A处理C2C12细胞24h,用RT-qPCR分析ATGL和HSL的mRNA水平。(C)表示用100μmol/L的羟基红花黄色素A分别处理C2C12细胞0、4、12、24h,用RT-qPCR分析ATGL和HSL的mRNA水平。数据用平均值±标准误差表示,每组三次平行。与对照相比,*,P<0.05;**,P<0.01;***,P<0.001(单因素方差分析)。
具体实施方式
实施例1
羟基红花黄色素A促进骨骼肌燃料选择偏好从葡萄糖转移到脂肪从而增强运动耐力表现作用的验证
1实验方法
1.1动物实验
购买自南京大学模型动物研究中心的5周雄性小鼠被饲养在无特定病原体的动物房中。在此期间,小鼠可以自由进食和饮水。动物房的暗/光循环为12小时,温度和湿度分别保持在23±2℃和50%±5%。本实验中的所有程序和方案均经江南大学动物伦理委员会标准批准。
小鼠适应两周后,将小鼠随机分为四组,包括对照组、HSYA治疗组(灌胃给药,50mg/kg/d)、运动组和运动-HSYA治疗组(灌胃给药,50mg/kg/d)。其中,对照组和运动组用生理盐水灌胃三周,剂量是按小鼠体重(g)*10μL。将HSYA溶于生理盐水,配置成5mg/mL的HSYA溶液,HSYA治疗组和运动-HSYA治疗组灌胃给药3周,剂量是小鼠体重(g)*10μL HSYA溶液。小鼠灌胃三周后,运动组和运动-HSYA治疗组被放置于跑步机和疲劳转棒系统进行适应训练,连续3天。3天后,我们使用相同的仪器对运动组和运动-HSYA治疗组的小鼠进行跑步测试和疲劳转棒测试。最后用CO2安乐死所有小鼠,收集小鼠的腓肠肌(GAS)、胫骨前肌(TA)和足底(SOL),将右腿GAS、SOL固定在4%多聚甲醛中,便于稍后进行油红染色,其余组织用液氮立即冷冻,再放入-80℃保存用于之后RNA的提取。
1.2油红染色
将肌肉(右腿GAS、SOL)固定在4%多聚甲醛中,随后将样品脱水并包埋在石蜡中。然后使用切片机将样品切割成5微米厚的切片。切片用油红O染色。用倒置光学显微镜来观察切片。
1.3细胞培养,细胞处理,尼罗红染色
C2C12小鼠成肌细胞被放置于37℃和5%CO2的细胞培养箱中培养,生长于含有10%胎牛血清和1%青霉素/链霉素的Dulbecco改良Eagle培养基中。当细胞长到培养皿的80%,将培养基中10%胎牛血清替换为2%马血清,从而诱导成肌细胞分化为肌管。
分化三天后,对C2C12肌管进行以下处理:(1)用0、20、50、100、200、400mM浓度梯度的羟基红花黄色素A处理C2C12肌管细胞12小时,(2)用100mM羟基红花黄色素A分别刺激C2C12肌管细胞0、4、12、24小时,(3)用0.4mM棕榈酸刺激C2C12肌管细胞12小时,随后将C2C12肌管细胞固定在甲醛中,并与尼罗红在室温下共同孵育10分钟。随后用4',6-二脒基-2-苯基吲哚固定细胞10分钟。用倒置光学显微镜来观察细胞染色情况。
1.4RNA提取和实时定量荧光PCR
使用Trizol从C2C12肌管或各种组织样本中提取总RNA。使用Nanodrop确认RNA质量,然后使用Prime Script RT系统进行cDNA合成。qRT-PCR在ABI7900 qRT-PCR系统上进行。每个样品做三次平行,使用的RT-PCR引物序列如下表1所示。
表1
2.实验结果
2.1羟基红花黄色素A显著增加了小鼠的耐力运动表现
从图2可以看出,与对照小鼠相比,补充羟基红花黄色素A的小鼠,其疲劳转棒时间,跑步时间,跑步距离显著增加。可见补充羟基红花黄色素A,的确可以提高耐力表现。
2.2羟基红花黄色素A促进小鼠骨骼肌中的燃料选择从葡萄糖转向脂肪
从图3可以看出,羟基红花黄色素A抑制了小鼠骨骼肌中糖酵解相关基因的表达。图4则表明羟基红花黄色素A促进了小鼠骨骼肌中脂肪酸氧化相关基因的表达。图5A表明补充羟基红花黄色素A减少了小鼠骨骼肌中的脂滴含量。和这个结果一致的是,图5B表明羟基红花黄色素A显著增加了小鼠骨骼肌中脂解相关基因的表达。综上所述,我们认为羟基红花黄色素A促进小鼠骨骼肌中的燃料选择从葡萄糖转向脂肪。
2.3羟基红花黄色素A促进C2C12细胞中的燃料选择从葡萄糖转向脂肪
我们在体外再次验证了羟基红花黄色素A对肌细胞燃料选择的影响。我们发现在不同浓度、不同时间的羟基红花黄色素A标品刺激下,C2C12细胞中的糖酵解相关基因的表达显著下降,而脂肪酸氧化和脂解相关基因的表达显著上升(图6,7,8B,C)。和体内实验结果一致,尼罗红染色表明羟基红花黄色素A处理显著降低了C2C12细胞中的脂滴含量。(图8A)
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
SEQUENCE LISTING
<110> 江南大学
<120> 羟基红花黄色素A在增强耐力中的应用
<130> BAA211512A
<160> 22
<170> PatentIn version 3.3
<210> 1
<211> 21
<212> DNA
<213> 人工序列
<400> 1
accgcagcta ggaataatgg a 21
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<400> 2
caaatgcttt cgctctggtc 20
<210> 3
<211> 20
<212> DNA
<213> 人工序列
<400> 3
cttcctgccc atgactgagg 20
<210> 4
<211> 21
<212> DNA
<213> 人工序列
<400> 4
gaccccagac gcacaaagta g 21
<210> 5
<211> 20
<212> DNA
<213> 人工序列
<400> 5
tgtggcctca ttcctcctac 20
<210> 6
<211> 20
<212> DNA
<213> 人工序列
<400> 6
tcgtggatgt tggtggagct 20
<210> 7
<211> 19
<212> DNA
<213> 人工序列
<400> 7
ccagcctgag ggcttactg 19
<210> 8
<211> 22
<212> DNA
<213> 人工序列
<400> 8
ctccattgac tgtgacatct cg 22
<210> 9
<211> 19
<212> DNA
<213> 人工序列
<400> 9
cggaatgggg agcctttgg 19
<210> 10
<211> 23
<212> DNA
<213> 人工序列
<400> 10
gccttcctta tccgtttcaa tgg 23
<210> 11
<211> 21
<212> DNA
<213> 人工序列
<400> 11
tgtggtccga gttggtatct t 21
<210> 12
<211> 20
<212> DNA
<213> 人工序列
<400> 12
gcacttccaa tcactgtgcc 20
<210> 13
<211> 19
<212> DNA
<213> 人工序列
<400> 13
gccgcctgga cattgactc 19
<210> 14
<211> 22
<212> DNA
<213> 人工序列
<400> 14
ccatgagaga aattcagccg ag 22
<210> 15
<211> 21
<212> DNA
<213> 人工序列
<400> 15
tatatgctgg accttcgcac a 21
<210> 16
<211> 20
<212> DNA
<213> 人工序列
<400> 16
ctccccgcca taaatgaggg 20
<210> 17
<211> 22
<212> DNA
<213> 人工序列
<400> 17
agatcaatcg gaccctagac ac 22
<210> 18
<211> 20
<212> DNA
<213> 人工序列
<400> 18
cagcgagtag cgcatagtca 20
<210> 19
<211> 21
<212> DNA
<213> 人工序列
<400> 19
actactgtgc ttcagggaca a 21
<210> 20
<211> 21
<212> DNA
<213> 人工序列
<400> 20
gcaaaggact tcgattctgc c 21
<210> 21
<211> 19
<212> DNA
<213> 人工序列
<400> 21
tgtggtgact gctgaccta 19
<210> 22
<211> 19
<212> DNA
<213> 人工序列
<400> 22
tgtggtgact gctgaccta 19
Claims (10)
1.羟基红花黄色素A或含羟基红花黄色素A的组合物在制备用于增强耐力的功能性食品或药品或保健品或运动模拟药中的用途。
2.根据权利要求1所述的用途,其特征在于,所述增强耐力包括延长机体运动时间、抑制糖酵解相关基因表达,促进脂肪酸氧化相关基因表达。
3.根据权利要求1所述的用途,其特征在于,所述功能性食品包括:功能性饮料、功能性冲剂、功能性泡腾片、功能性饼干、功能性胶囊等。
4.根据权利要求1所述的用途,其特征在于,所述药品包括用于治疗骨骼肌慢性疾病和/或治疗骨骼肌损伤的药物,模拟运动刺激的药物。
5.根据权利要求4所述的用途,其特征在于,所述骨骼肌慢性疾病包括:骨质疏松、肌少症、慢性骨骼肌损伤等。
6.根据权利要求1所述的用途,其特征在于,所述保健品包括:用于提升耐力和/或缓解疲劳等的保健食品。
7.用于增强耐力的组合物,其特征在于,所述组合物为含有羟基红花黄色素A或羟基红花黄色素A衍生物的组合物。
8.根据权利要求7所述的用于增强耐力的组合物,其特征在于,所述组合物包括功能性食品或药品或保健品或运动模拟药。
9.根据权利要求8所述的用于增强耐力的组合物,其特征在于,所述组合物,还包括药学上接受的辅料,包括溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂、释放阻滞剂等。
10.根据权利要求7或8所述的用于增强耐力的组合物,其特征在于,还可以包含其他对机体耐力有利的补充成分,选自蛋白质、分支或不分支氨基酸、单糖或复合糖、肌酐、电解质、肌酸、维生素、矿物质以及补充训练饮食的其他因子。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111317801.7A CN114098074A (zh) | 2021-11-09 | 2021-11-09 | 羟基红花黄色素a在增强耐力中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111317801.7A CN114098074A (zh) | 2021-11-09 | 2021-11-09 | 羟基红花黄色素a在增强耐力中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114098074A true CN114098074A (zh) | 2022-03-01 |
Family
ID=80377601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111317801.7A Pending CN114098074A (zh) | 2021-11-09 | 2021-11-09 | 羟基红花黄色素a在增强耐力中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114098074A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150025030A1 (en) * | 2013-02-07 | 2015-01-22 | Zhejiang Yongning Pharmaceutical Co Ltd | Hydroxysafflor yellow A sodium and preparation as well as application thereof |
CN104721152A (zh) * | 2015-01-20 | 2015-06-24 | 哈尔滨医科大学 | 一种羟基红花黄色素a冻干粉针剂的制备方法及其产品 |
CN104721179A (zh) * | 2015-01-20 | 2015-06-24 | 哈尔滨医科大学 | 羟基红花黄色素a在制备治疗缺氧性肺动脉高压的保健药物或功能食品中的用途 |
CN112641916A (zh) * | 2020-12-30 | 2021-04-13 | 辽宁上药好护士药业(集团)有限公司 | 一种强身健体的中药膏方及其制备方法 |
-
2021
- 2021-11-09 CN CN202111317801.7A patent/CN114098074A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150025030A1 (en) * | 2013-02-07 | 2015-01-22 | Zhejiang Yongning Pharmaceutical Co Ltd | Hydroxysafflor yellow A sodium and preparation as well as application thereof |
CN104721152A (zh) * | 2015-01-20 | 2015-06-24 | 哈尔滨医科大学 | 一种羟基红花黄色素a冻干粉针剂的制备方法及其产品 |
CN104721179A (zh) * | 2015-01-20 | 2015-06-24 | 哈尔滨医科大学 | 羟基红花黄色素a在制备治疗缺氧性肺动脉高压的保健药物或功能食品中的用途 |
CN112641916A (zh) * | 2020-12-30 | 2021-04-13 | 辽宁上药好护士药业(集团)有限公司 | 一种强身健体的中药膏方及其制备方法 |
Non-Patent Citations (3)
Title |
---|
WEIWEI FAN 等: "PPARδ Promotes Running Endurance by Preserving Glucose", 《CELL METABOLISM》 * |
梁晓伟等: "羟基红花黄色素A对人骨髓间充质干细胞成骨分化的影响", 《口腔生物医学》 * |
鞠国泉等: "红花在运动饮料中的应用", 《食品工业》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102133392B (zh) | 促进虾蟹蜕壳硬壳和防病抗应激的水体泼洒复合制剂 | |
CN102014945B (zh) | 具有高含量的1,25-二羟基维生素d3糖苷和槲皮甙的粉绿叶茄植物提取物的制备及其应用 | |
CN101690722B (zh) | 减肥组合物 | |
CN108272968A (zh) | 含辅酶q10与小麦胚芽油的组合物在制备预防骨质疏松的保健食品及药品的应用 | |
CN108685934B (zh) | 京尼平苷在促进骨骼肌快肌生成中的应用 | |
US20210308199A1 (en) | Active substance of morchella, its use and a composition thereof for improving the reproductive function | |
CN102058631B (zh) | 沙棘叶提取物制剂及其制备方法 | |
CN102552411A (zh) | 一种鲟鱼鱼种用中草药免疫增强剂 | |
TWI830696B (zh) | 抑制肌纖維變性用組成物 | |
KR20170116532A (ko) | 마카 및 대추야자, 영지버섯, 녹용 발효추출물을 유효성분으로 함유하는 운동수행능력 증진 및 피로회복 증진용 복합조성물 | |
CN1777418B (zh) | 减肥组合物 | |
KR20130019826A (ko) | 항비만 효과를 가지는 진피 발효 추출물의 제조방법과 그 진피 발효 추출물 | |
CN114098074A (zh) | 羟基红花黄色素a在增强耐力中的应用 | |
CN104940241B (zh) | 一种防治妇女更年期综合征的硒虫草复方制剂 | |
CN102596214B (zh) | 改善脂肪肝的组合物 | |
CN101214052B (zh) | 一种具有缓解体力疲劳、增强免疫功能的保健食品 | |
CN102125129B (zh) | 一种保健茶 | |
US20080119386A1 (en) | Nutritional formula for athletes' recovery | |
KR20220110443A (ko) | 만병초, 당삼, 또는 고삼 추출물 또는 이로부터 분리된 물질을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 또는 근기능 개선용 조성물 | |
CN111773323A (zh) | 石斛水提取物在治疗2型糖尿病的应用 | |
Joshi et al. | Sportsmen’s energy package Cordyceps sinensis: Medicinal importance and responsible phytochemical constituents | |
CN110522028A (zh) | 一种护肝抗疲劳的组合物及其应用 | |
CN108244638A (zh) | 马兰发酵物及其制备方法和用途 | |
CN108186699A (zh) | 一种具有抗疲劳功效的中药提取物滴丸及其制备方法 | |
KR20140145666A (ko) | 갈조소, 유근피 및 저분자 알긴산의 천연 복합물을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |